Receptor activator of nuclear factor-κB ligand and osteoprotegerin: Potential implications for the pathogenesis and treatment of malignant bone diseases

Cancer

Volumn 92, Issue 3, 2001, Pages 460-470

  Hofbauer, Lorenz C ^a   Neubauer, Andreas ^a   Heufelder, Armin E ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Bone; Bone resorption; Cancer; Humoral hypercalcemia of malignancy; Metastasis; Multiple myeloma; Osteoprotegerin; Receptor activator of nuclear factor B (RANK); Receptor activator of nuclear factor B receptor ligand (RANKL)

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN;

ARTICLE; BONE CANCER; HUMAN; KNOCKOUT MOUSE; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; PATHOGENESIS; PRIORITY JOURNAL; TRANSGENIC MOUSE;

ANTINEOPLASTIC AGENTS; BONE DISEASES; BONE NEOPLASMS; CARRIER PROTEINS; GLYCOPROTEINS; HUMANS; MEMBRANE GLYCOPROTEINS; NEOPLASM METASTASIS; OSTEOPROTEGERIN; PROGNOSIS; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR MARKERS, BIOLOGICAL;

EID: 0035423780     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0142(20010801)92:3<460::AID-CNCR1344>3.0.CO;2-D     Document Type: Article

References (105)

1. Pathophysiologic interactions in skeletal metastasis
2. Molecular mechanisms of osteolytic bone metastases
3. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families
4. TRANCE is a TNF family member that regulates dendritic cell and osteoclast function
5. Osteoprotegerin and osteoprotegerin ligand mediate the local regulation of bone resorption
6. The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption
7. Osteoprotegerin (OPG) ligand is a cytokine that regulates osteoclast differentiation and activation
8. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TBANCE/RANKL
9. TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-jun N-terminal kinase in T cells
10. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function
11. Evidence for a role of a tumor necrosis factor-α (TNF-α)-converting enzyme-like protease in shedding of TRANCE, a TNF family member involved in osteoclastogenesis and dendritic cell survival
12. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand
13. Cancer cells responsible for humoral hypercalcemia express mRNA encoding a secreted form of ODF/TRANCE that induces osteoclast formation
14. Localization of RANKL (Receptor activator of NFκB ligand) mRNA and protein in skeletal and extraskeletal tissues
15. A combination of osteoclast differentiation factor and macrophage-colony stimulating factor is sufficient for both human and mouse osteoclast formation in vitro
16. Osteoclast differentiation factor (ODF) induces osteoclast-like cell formation in human peripheral blood mononuclear cell cultures
17. TRANCE is necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts
18. The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts
19. Osteoclast differentiation factor acts as a multifunctional regulator in murine osteoclast differentiation and function
20. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis
21. The role of osteoprotegerin and osteoprotegerin ligand in the pathogenesis and treatment of metabolic bone diseases
22. TRANCE (Tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor
23. TRANCE, a TNF family member, is differentially expressed on T cell subsets and induces cytokine production in dendritic cells
24. TRANCE, a tumor necrosis factor family member critical for CD40 ligand-independent T helper cell activation
25. Osteoprotegerin: A novel secreted protein involved in the regulation of bone density
26. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): A mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro
27. Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis
28. Characterization of a novel TNF-like ligand and recently described TNF ligand and TNF receptor superfamily genes and their constitutive and inducible expression in hematopoietic and non-hematopoietic cells
29. TR1, a new member of the tumor necrosis factor receptor family, induces fibroblast proliferation and inhibits osteoclastogenesis and bone resorption
30. OPG/FDCR-1, a TNF receptor family member, is expressed in lymphoid cells and is up-regulated by ligating CD40
31. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL
32. Osteoprotegerin production by human osteoblast lineage cells is stimulated by vitamin D, bone morphogenetic protein-2, and cytokines
33. Structure of the mouse osteoclastogenesis inhibitory factor/osteoprotegerin gene and its expression in embryogenesis
34. Establishment and characterization of an immortal macrophage-like cell line inducible to differentiate to osteoclasts
35. Osteoclastogenesis-inhibitory factor suppresses osteoclast survival by interfering in the interaction of stromal cells with osteoclast
36. Osteoclastogenesis inhibitory factor (OCIF) directly inhibits bone-resorbing activity of isolated mature osteoclasts
37. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification
38. Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin
39. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand
40. RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis
41. Activation of NF-κB by RANK requires tumor necrosis factor receptor-associated factor (TRAF) 6 and NF-κB-inducing kinase. Identification of a novel TRAF6 interaction motif
42. The TRAF family of signal transducers mediates NF-κB activation by the TRANCE receptor
43. TRANCE, a TNF family member, activates Akt/PKB through a signaling complex involving TRAF6 and c-Src
44. RANKing the importance of measles virus in Paget's disease
45. Commitment and differentiation of osteoclast precursor cells by the sequential expression of c-fms and receptor activator of nuclear factor κB (RANK) receptors
46. Sequential requirements for SCL/tal-1, GATA-2, macrophage colony-stimulating factor, and osteoclast differentiation factor/osteoprotegerin ligand in osteoclast development
47. RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism
48. RANK is essential for the osteoclast and lymph node development
49. TRAF6-deficiency results in osteopetrosis and defective interleukin-1, CD40 and LPS signaling
50. Osteopetrosis in mice lacking NF-κB1 and NF-κB2
51. Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells
52. 17β-Estradiol stimulates expression of osteoprotegerin (OPG)/osteoclastogenesis inhibitory factor (OCIF) by a mouse stromal cell line, ST-2
53. Osteoprotegerin gene expression in proliferating chondrocytes in intact and ovariectomized rats
54. Expression of osteoclast differentiation factor (ODF/RANKL/OPGL) in trabecular bone and bone marrow B-lymphocytes in OVX mice
55. Expression and regulation of osteoprotegerin (OPG) and osteoclast differentiation factor (ODF) in mice
56. Estrogen decreases osteoclast formation by down-regulating RANKL-induced JNK activation
57. Estrogens suppress RANK ligand-induced osteoclast differentiation via a stromal cell independent mechanism involving c-Jun repression
58. The effect of a single dose of osteoprotegerin in postmenopausal women
59. Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: Potential paracrine mechanisms of glucocorticoid-induced osteoporosis
60. Osteoprotegerin mRNA is expressed in primary human osteoblast-like cells: Down-regulation by glucocorticoids
61. Glucocorticoid decreases circulating osteoprotegerin (OPG): Possible mechanism for glucocorticoid induced osteoporosis
62. Activated T cells support osteoclast formation in vitro
63. Involvement of receptor activator of nuclear factor κB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis
64. Involvement of receptor activator of nuclear factor κB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis
65. Expression of osteoclast differentiation factor at sites of bone erosion in collagen-induced arthritis
66. Parathyroid hormone stimulates TRANCE and inhibits osteoprotegerin messenger ribonucleic acid expression in murine bone marrow cultures: Correlation with osteoclast-like cell formation
67. Osteotropic agents regulate the expression of osteoclast differentiation factor and osteoprotegerin in osteoblastic stromal cells
68. 3 hypersensitivity of osteoclast precursors from patients with Paget's disease
69. Enhanced RANK ligand expression and responsivity of bone marrow cells in Paget's disease of bone
70. Mutations in TNFRSF11A, affecting the signal peptide of RANK, cause familial expansile osteolysis
71. Bone marrow, cytokines, and bone remodeling: Emerging insights into the pathophysiology of osteoporosis
72. The physiology of parathyroid hormone-related protein
73. Gene expression of osteoprotegerin ligand, osteoprotegerin and receptor activator of NF-κB in giant cell tumor of bone: Possible involvement in tumor cell-induced osteoclast-like cell formation
74. Expression of osteoclast differentiation signals by stromal elements of giant cell tumors
75. Loss of RANKL, a TNF-alpha ligand family member, in sporadic osteosarcoma
76. Common mechanisms of osteosarcoma and Paget's disease
77. Paget's disease of bone: Evidence for a susceptibility locus on chromosome 18q and for genetic heterogeneity
78. Evidence for a novel osteosarcoma tumor-suppressor gene in the chromosome 18 region genetically linked with Paget disease of bone
79. Mechanisms of bone lesions in multiple myeloma and lymphoma
80. Heterogeneity in response to interleukin 6 (IL-6) expression of IL-6 and IL-6 receptor mRNA in a panel of established human multiple myeloma cell lines
81. Parathyroid hormone-related protein in hypercalcemia associated with hematological malignancy
82. Parathyroid hormone-related protein mRNA and protein expression in multiple myeloma: A case report
83. 3 or parathyroid hormone
84. ODF/OPGL expression is regulated by IL-1 and IL-6
85. Breast cancer cells interact with osteoblasts to support osteoclast formation
86. Osteoclast differentiation factor (ODF/OPGL/RANKL/TRANCE) expression in bone invasion model of breast cancer
87. Breast cancer cells increase osteoclastogenesis by secreting M-CSF and by upregulating RANKL in bone marrow stromal cells in a gp130-dependent fashion
88. Human multiple myeloma cell lines express mRNA for osteoclast differentiation factor
89. New insights into role of microenvironment in multiple myeloma
90. Evidence for a causal role of parathyroid hormone-related in the pathogenesis of human breast cancer-mediated osteolysis
91. Interactions between cancer and bone marrow cells induce osteoclast differentiation factor expression and osteoclast-like cell formation in vitro
92. Prostate carcinoma: Production of bioactive factors
93. Osteoprotegerin and TRANCE are differentially expressed by prostate cancer cells in vitro and in vivo
94. Characterization of monomeric and homodimeric forms of osteoclastogenesis inhibitory factor
95. Osteoclastogenesis inhibitory factor exhibits hypocalcemic effects in normal mice and in hypercalcemic nude mice carrying tumors associated with humoral hypercalcemia of malignancy
96. Osteoprotegerin (OPG), a novel TNF-receptor family member, profoundly inhibits endosteal bone resorption due to growth, humoral hypercalcemia of malignancy, and interleukin 1
97. 3
98. Hypocalcemic effect of osteoclastogenesis inhibitory factor/osteoprotegerin in the thyroparathyroidectomized rat
99. Comparison of the inhibitory effects of osteoprotegerin and of APD on PTHrP-mediated hypercalcemia and bone remodeling
100. Osteoprotegerin prevents and reverses hypercalcemia in a murine model of humoral hypercalcemia of malignancy
101. Osteoprotegerin prevents osteolytic bone destruction in both athymic and syngeneic models of experimental tumor metastasis to bone
102. Efficacy of a genetically engineered soluble receptor activator of NF-κB (RANK) fusion protein on bone resorption in vitro and in vivo
103. Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord
104. Osteoprotegerin mitigates tail suspension-induced osteopenia
105. Adenoviral delivery of osteoprotegerin ameliorates bone resorption in a mouse ovariectomy model of osteoporosis